Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance-Reference-Cited by-同舟云学术

Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance

Published:2020-08-20 Issue:9 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Van den Kerkhof M.¹,Mabille D.¹,Hendrickx S.¹,Leprohon P.²,Mowbray C. E.³,Braillard S.³,Ouellette M.²,Maes L.¹,Caljon G.¹^ORCID

Affiliation:

1. Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, Belgium

2. Centre de Recherche en Infectiologie du Centre de Recherche du Centre Hospitalier Universitaire de Québec, Université Laval, Québec, Québec, Canada

3. Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

Abstract

Current antileishmanial treatment is hampered by limitations, such as drug toxicity and the risk of treatment failure, which may be related to parasitic drug resistance. Given the urgent need for novel drugs, the Drugs for Neglected Diseases initiative (DND i ) has undertaken a drug discovery program, which has resulted in the identification of aminopyrazoles, a highly promising antileishmanial chemical series. Multiple experiments have been performed to anticipate the propensity for resistance development.

Funder

Dutch Ministry of Foreign Affairs

UK Aid

Bill and Melinda Gates Foundation

World Health Organization

Canada Research Chairs

Fonds Wetenschappelijk Onderzoek

Gouvernement du Canada | Canadian Institutes of Health Research

Bundesministerium für Bildung und Forschung

Universiteit Antwerpen

Global Health Innovative Technology Fund

Publisher